Halozyme reports pancreatic cancer trial success
San Diego’s Halozyme Therapeutics reported positive clinical results for the use of its drug PEGPH20 in combination therapy for pancreatic cancer.
Among the results, a Phase 2 trial found a statistically significant increase in survival without progression of patients with Stage IV pancreatic cancer. These patients experienced a median 8.6 months in progression-free survival compared to 4.5 months among control patients, a primary endpoint.
That trial also achieved its primary endpoint of reduction in the rate of blood clots in the treated group.
Shares of Halozyme closed Thursday after the announcement at $12.61 apiece, up $1.92 or 18 percent.
Read more: http://www.sandiegouniontribune.com/business/biotech/sd-me-halozyme-jumps-20170105-story.html
